Strategic advice and creative problem solving

Mark Bina is an experienced legal counselor and litigator who represents clients in multiple industries, with a focus on healthcare providers. Representing a full range of healthcare providers and other businesses, Mark helps clients navigate:

• Disputes, investigations and litigation, especially defending health providers against and appealing administrative enforcement actions.
• Healthcare regulatory and business issues as outside general counsel
• Business litigation, dispute resolution and risk management

Clients turn to Mark as a steady hand who is both diplomatic and creative in navigating complex regulatory issues and litigation. They know he works to solve not only today's challenges, but to see "around the corner" and help them avoid future problems, too.

Mark previously served as the executive director of the Indiana Board of Pharmacy and later as an assistant attorney general with the Illinois Attorney General's Office.

Mark is co-chair of the Healthcare Litigation team.

Bar Admissions

• District of Columbia
• Illinois

Education

• Northwestern University, Kellogg School of Management, Certificate, Quarles & Brady Leadership Program (2025)

• University of Illinois Chicago School of Law (J.D., 2006)
  • John Marshall Law Review, staff editor

• Indiana University Bloomington (B.A., with distinction, 2000)

• "Best Practices in Defending (and Appealing) Disciplinary Cases"
• "Constitutional Challenges to Pharmacy Statutes and Regulations"
• "David v. Goliath: Managing Surveys, Appeals, and Government Investigations"
• "Enforcement Actions: Trends & Takeaways"
• Chicago Commissioner of Public Health Publishes Proposed Pharmaceutical Representative Licensing Rules
• City of Chicago Imposes Licensing Requirement Upon Pharmaceutical Representatives
• COVID-19: Illinois Executive Order Grants Civil Immunity to Assisted Living Providers
• Diving into the Washington My Health My Data Act
• Diving into the Washington My Health My Data Act
• DOJ, State AGs Innovate to Fight Covid-19 Fraud
• Health Care Reform: Increased Focus on Fraud & Abuse Issues
• Hiring Wisely: Enforceability of Employment Agreements, Covenants Not to Compete, and Non-Solicitation/Confidentiality Clauses
• Homecare Law: The Good, The Bad, and The Ugly
• Illinois to Require Prescribers to Check the PMP Before Writing Initial Prescriptions for Schedule II Narcotics
• Kentucky Attorney General Determines Board of Pharmacy Lacks Statutory Authority to Regulate Non-Resident Pharmacists
• New CMS Regulation Prohibits Nursing Facilities from Using Pre-Admission Binding Arbitration Agreements
• PPACA Health Reform Update, HITECH Act, and Fraud and Abuse Laws
• Quarles Partners Assess Risks to COVID-19 Testing Labs of Increased FCA Scrutiny in Article for Bloomberg Law
• Recordkeeping for the New Lawyer: Elements of an Effective Legal Practice
• SEC Rules Impose New Four-Day Reporting Requirements for Cybersecurity Incidents
• The Travel Act in Federal Health Care Fraud Prosecutions
• Treating Pain Management Patients Effectively
• US Supreme Court Confirms Enforceability of Health Care Arbitration Agreements
• When Healthcare Becomes a Crime
• ​Supreme Court's Decision in KBR Inc. v. U.S. ex rel Carter Confirms that False Claims Act Statute of Limitations Is Not Tolled Under WSLA, but May Expose Health Care Providers to "Copycat" False Claim Act Suits Under "First-to-File" Rule
• ​U.S. Supreme Court Rules that State Licensing Board Is Not Immune From Anti-Trust Claims

Seminar

• 2015 Pharmacy Law Symposium
• 2018 Pharmacy Law Symposium
• 2021 Pharmacy Law Symposium
• 2022 Pharmacy Law Symposium
• 2023 Pharmacy Law Symposium
• 2025 Pharmacy Law Symposium
• 2026 Pharmacy Law Symposium
• What Do Payors Need to Be Aware of with Respect to PBM Litigation